Healthcare stocks have finally stepped back into the spotlight. After spending much of the past several years in the shadow of technology and AI, the sector has quietly emerged as one of the year's more compelling comeback stories.
Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy
Designed to provide broad exposure to the Health Care ETFs category of the market, the iShares Biotechnology ETF (IBB) is a smart beta exchange traded fund launched on 02/05/2001.
| XHAN Exchange | US Country |
The described company operates as an investment fund focused on tracking the performance of a specific underlying index. By investing at least 80% of its assets in the securities that comprise the index, the fund aims to mimic the index's returns and behavior closely. This strategy indicates a focus on providing investors with exposure to the components of a particular market or sector through the index it follows. However, it is noteworthy that the fund is characterized as non-diverse, which means it may concentrate its investments in a particular sector, company, or geographical area, potentially increasing the risk of volatility and loss due to lack of diversification.
The fund offers a targeted investment product that primarily focuses on securities from its underlying index, alongside additional financial instruments to potentially enhance returns and manage risks: